MDM2 antagonist improves therapeutic activity of azacitidine in myelodysplastic syndromes and chronic myelomonocytic leukemia

1. Wei, Y.
2. Zheng, H.
3. Lockyer, P.P.
4. Darbaniyan, F.
5. Li, Z.
6. Kanagal-Shamanna, R.
7. Soltysiak, K.A.
8. Yang, H.
9. Ganan-Gomez, I.
10. Montalban-Bravo, G.
11. Chien, K.S.
12. Do, K.-A.
13. Daver, N.
14. Garcia-Manero, G.